SB387
Regards Medicaid managed care coverage of pharmacogenomic testing
📋 What This Bill Does
The bill requires Medicaid managed care organizations in Ohio to cover pharmacogenomic testing deemed medically necessary for Medicaid enrollees with depression or anxiety. Prior authorization requirements are allowed but should not create barriers to care.
Plain English summary · Non-partisan · Auto-generated
Rationale
The bill aligns with libertarian principles of individual liberty by potentially improving healthcare access for individuals on Medicaid. It also touches on limited government by setting criteria for prior authorization to avoid unnecessary administrative burdens. However, it may raise concerns over government involvement in healthcare decisions and potential cost implications.
Risks and Concerns
- Government mandating specific healthcare coverage may infringe on individual's right to choose their own healthcare options.
- Imposing fines or penalties on managed care organizations for noncompliance could lead to increased costs for these organizations, ultimately affecting consumers.
- Establishing reporting processes for noncompliance may increase bureaucracy and government oversight in healthcare.